常规化疗与吉非替尼序贯治疗老年晚期肺腺癌近期疗效观察

毕国斌; 蒋涛; 苏玉璇; 左金曼

常规化疗与吉非替尼序贯治疗老年晚期肺腺癌近期疗效观察

The short-term effect of the sequential therapy of conventional chemotherapy combined with gefitinib in the treatment of advanced lung adenocarcinoma in elderly patients

摘要

摘要: 目的：观察常规化疗与吉非替尼序贯治疗老年晚期肺腺癌近期疗效及不良反应。方法：选择15例初治老年晚期肺腺癌患者，给予常规化疗序贯吉非替尼治疗：常规化疗，每3周重复，最多不超过6个周期，化疗疗程结束或化疗中出现病情进展后给予吉非替尼治疗，至疾病进展或不良反应不能耐受时停药。观察近期疗效及不良反应。结果：15例患者均可评价疗效，其中完全缓解0例，部分缓解5例（33.3%），疾病稳定7例（46.7%），疾病进展3例（20.0%），有效率33.3%，疾病控制率为80.0%，1年生存率为33.3%。主要不良反应为骨髓抑制、消化道反应及皮疹等。结论：常规化疗与吉非替尼序贯治疗老年晚期肺腺癌疗效确切，安全性较好。

Abstract: Objective: To observe the effects and adverse reactions of the sequential therapy of conventional chemotherapy combined with gefitinib in the treatment of advanced lung adenocarcinoma in elderly patients.Methods: Fifteen elderly patients with advanced lung adenocarcinoma were treated with conventional chemotherapy one cycle every 3 weeks for less than six cycles,the gefitinib was used after chemotherapy or disease progression during chemotherapy until the patients could not tolerate.The short-term effects and adverse reactions of the patients were observed.Results: Among 15 patients,partial remission in 5 cases(33.3%),stable disease in 7 cases(46.7%) and disease progression in 3 cases(20.0%) were found,the effective rate,disease control rate and 1-year survival rate of which were 33.3%,80.0%,and 33.3%,respectively.The bone marrow suppression,gastrointestinal reaction and skin rash were the major adverse reactions.Conclusions: The sequential therapy of conventional chemotherapy combined with gefitinib in the treatment of advanced lung adenocarcinoma in elderly patients is good and safe.

HTML全文

参考文献(9)

施引文献

资源附件(0)